Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Abington Memorial Hospital
mi
from
Abington, PA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Lankenau Medical Center
mi
from
Wynnewood, PA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Lankenau Medical Center
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Women and Infants Hospital
mi
from
Providence, RI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Northwest Hospital
mi
from
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Northwest Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Washington Medical Center
mi
from
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Vincent Hospital
mi
from
Green Bay, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Bay Area Medical Center
mi
from
Marinette, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated:  9/8/2017
NYU Clinical Cancer Center
mi
from
New York, NY
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated: 9/8/2017
NYU Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated:  9/8/2017
NYU Rusk Institute of Rehabilitation Medicine
mi
from
New York, NY
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated: 9/8/2017
NYU Rusk Institute of Rehabilitation Medicine
mi
from
New York, NY
Click here to add this to my saved trials
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated:  9/8/2017
Tisch Hospital
mi
from
New York, NY
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated: 9/8/2017
Tisch Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery
A Phase 2 Study of GTX-SRS: Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery for Borderline Resectable Pancreatic Cancer
Status: Enrolling
Updated:  9/8/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery
A Phase 2 Study of GTX-SRS: Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery for Borderline Resectable Pancreatic Cancer
Status: Enrolling
Updated: 9/8/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Methylselenocysteine Effects on Circadian Rhythm
Chemoprevention of Breast and Prostate Cancers in Shift Workers by Dietary Methylselenocysteine: Effects on Circadian Rhythm and Estrogen Receptor-B Cycling
Status: Enrolling
Updated:  9/11/2017
Environmental and Occupational Health Sciences Institute
mi
from
Piscataway, NJ
Methylselenocysteine Effects on Circadian Rhythm
Chemoprevention of Breast and Prostate Cancers in Shift Workers by Dietary Methylselenocysteine: Effects on Circadian Rhythm and Estrogen Receptor-B Cycling
Status: Enrolling
Updated: 9/11/2017
Environmental and Occupational Health Sciences Institute
mi
from
Piscataway, NJ
Click here to add this to my saved trials
Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer
Identification of Predictors of Tolerance to Chemoradiotherapy in Elderly Patients With Head and Neck Cancer
Status: Enrolling
Updated:  9/11/2017
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer
Identification of Predictors of Tolerance to Chemoradiotherapy in Elderly Patients With Head and Neck Cancer
Status: Enrolling
Updated: 9/11/2017
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II
Status: Enrolling
Updated:  9/11/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II
Status: Enrolling
Updated: 9/11/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
The Effect of Walking on Fatigue After Chemotherapy in Patients 65 and Older
A Randomized, Wait-list Controlled Clinical Trial: the Effect of a Physical Activity Program on Fatigue After Potentially Curative Chemotherapy Among Cancer Survivors Age 65 or Older -- PACT (Physical Activity After Chemotherapy)
Status: Enrolling
Updated:  9/11/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
The Effect of Walking on Fatigue After Chemotherapy in Patients 65 and Older
A Randomized, Wait-list Controlled Clinical Trial: the Effect of a Physical Activity Program on Fatigue After Potentially Curative Chemotherapy Among Cancer Survivors Age 65 or Older -- PACT (Physical Activity After Chemotherapy)
Status: Enrolling
Updated: 9/11/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
The CARE Program: CAncer REhabilitation Pilot Study for Older Adults
LCCC 1409: The CARE Program: CAncer REhabilitation Pilot Study for Older Adults
Status: Enrolling
Updated:  9/11/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
The CARE Program: CAncer REhabilitation Pilot Study for Older Adults
LCCC 1409: The CARE Program: CAncer REhabilitation Pilot Study for Older Adults
Status: Enrolling
Updated: 9/11/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy
Pilot Study of Intensity Modulated Radiotherapy (IMRT) to Pelvis Post-Hysterectomy With Analysis of Clinical Target Volume Motion and Relation to Position and Volume of Bladder and Rectum During Course of Radiotherapy for Use in Optimization of Margin Size
Status: Enrolling
Updated:  9/11/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy
Pilot Study of Intensity Modulated Radiotherapy (IMRT) to Pelvis Post-Hysterectomy With Analysis of Clinical Target Volume Motion and Relation to Position and Volume of Bladder and Rectum During Course of Radiotherapy for Use in Optimization of Margin Size
Status: Enrolling
Updated: 9/11/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
Flaxseed vs. Aromatase Inhibitors: Breast Tumor Characteristics and Prognosis
Status: Enrolling
Updated:  9/11/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
Flaxseed vs. Aromatase Inhibitors: Breast Tumor Characteristics and Prognosis
Status: Enrolling
Updated: 9/11/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy
Status: Enrolling
Updated:  9/12/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy
Status: Enrolling
Updated: 9/12/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Gynecologic Oncology of West Michigan
mi
from
Grand Rapids, MI
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Gynecologic Oncology of West Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Women's Institute for Gynecologic Cancer and Special Pelvic Surgery
mi
from
Phillipsburg, NJ
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Women's Institute for Gynecologic Cancer and Special Pelvic Surgery
mi
from
Phillipsburg, NJ
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Winthrop University Hospital
mi
from
Mineola, NY
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
UC Irvine Health/Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
UC Irvine Health/Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Stanford Cancer Institute
mi
from
Palo Alto, CA
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Stanford Cancer Institute
mi
from
Palo Alto, CA
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Beebe Medical Center
mi
from
Lewes, DE
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Northside Hospital
mi
from
Atlanta, GA
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Northwestern University
mi
from
Chicago, IL
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Northwestern Medicine Cancer Center Warrenville
mi
from
Warrenville, IL
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Northwestern Medicine Cancer Center Warrenville
mi
from
Warrenville, IL
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Saint Vincent Oncology Center
mi
from
Indianapolis, IN
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Saint Vincent Oncology Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Greater Baltimore Medical Center
mi
from
Baltimore, MD
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated:  9/12/2017
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
Status: Enrolling
Updated: 9/12/2017
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials